Literature DB >> 21878854

Hemicentral retinal vein occlusion: natural history of visual outcome.

Sohan Singh Hayreh1, M Bridget Zimmerman.   

Abstract

PURPOSE: To investigate the natural history of visual outcome in hemicentral retinal vein occlusion (HCRVO).
METHODS: The study comprised 65 consecutive HCRVO patients (67 eyes) seen within 3 months of onset. At first visit, all patients had a detailed ophthalmic and medical history and comprehensive ophthalmic evaluation. Ophthalmic evaluation at initial and follow-up visits included recording visual acuity using the Snellen visual acuity chart, and visual fields with a Goldmann perimeter. Hemicentral retinal vein occlusion was classified into nonischemic (57 eyes) and ischemic (10 eyes) at initial visit.
RESULTS: Nonischemic HCRVO involved superior and inferior half of the retina in 39% and 56%, respectively, and in ischemic HCRVO in 50% and 40%, respectively. In nonischemic HCRVO, initial visual acuity was 20/60 or better in 73.7% and minimal to mild visual field loss in 96% and in ischemic HCRVO in 40% and 55.5%, respectively. After resolution of macular edema, in nonischemic HCRVO eyes, cumulative chance of improvement was 50% with 20/70 or worse initial visual acuity, and deterioration in only 6% with 20/60 or better initial visual acuity, and in 5% with minimal to mild visual initial field loss.
CONCLUSION: This study suggests a good prognosis in the natural history of visual outcome in nonischemic HCRVO.

Entities:  

Mesh:

Year:  2012        PMID: 21878854     DOI: 10.1097/IAE.0b013e31821801f5

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

Review 1.  Ocular vascular occlusive disorders: natural history of visual outcome.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2014-04-21       Impact factor: 21.198

2.  Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusion.

Authors:  Vlad M Matei; Jonathan Y Xia; Chan Nguyen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-21       Impact factor: 3.117

3.  Comment on 'The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary'.

Authors:  S S Hayreh
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

4.  Fundus changes in branch retinal vein occlusion.

Authors:  Sohan Singh Hayreh; M Bridget Zimmerman
Journal:  Retina       Date:  2015-05       Impact factor: 4.256

5.  Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14.

Authors:  Ingrid U Scott; Paul C Vanveldhuisen; Neal L Oden; Michael S Ip; Amitha Domalpally; Bernard H Doft; Michael J Elman; Barbara A Blodi
Journal:  Arch Ophthalmol       Date:  2012-12

6.  SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.

Authors:  Andrew Hendrick; Paul C VanVeldhuisen; Ingrid U Scott; Jacquie King; Barbara A Blodi; Michael S Ip; Rahul N Khurana; Neal L Oden
Journal:  Am J Ophthalmol       Date:  2020-08-20       Impact factor: 5.258

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.